These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26270511)

  • 1. Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure.
    Donohoe K; Levine R
    J Thromb Haemost; 2015 Oct; 13(10):1787-9. PubMed ID: 26270511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor V Inhibitors: A Diagnostic and Therapeutic Challenge.
    Olson NJ; Ornstein DL
    Arch Pathol Lab Med; 2017 Dec; 141(12):1728-1731. PubMed ID: 29189062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe coagulopathy following intraoperative use of topical thrombin.
    Sarfati MR; Dilorenzo DJ; Kraiss LW; Galt SW
    Ann Vasc Surg; 2004 May; 18(3):349-51. PubMed ID: 15354638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acquired factor V deficiency: a rare bleeding disorder with variable clinical presentations].
    Alcantara M; Ducastelle S; Rugeri L; Dargaud Y
    Rev Med Interne; 2011 May; 32(5):e59-61. PubMed ID: 20638758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases.
    Poynton AR; Nelson MC; McCance SE; Levine RL; O'Leary PF
    Spine (Phila Pa 1976); 2003 Jun; 28(12):E221-3. PubMed ID: 12811284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
    Streiff MB; Ness PM
    Transfusion; 2002 Jan; 42(1):18-26. PubMed ID: 11896308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential value of thrombin generation assay in the diagnosis of FV inhibitors.
    Désage S; Jousselme E; Le Quellec S; Lienhart A; Nougier C; Dargaud Y; Jourdy Y
    Int J Lab Hematol; 2019 Oct; 41(5):e117-e120. PubMed ID: 30953579
    [No Abstract]   [Full Text] [Related]  

  • 8. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
    Tarantino MD; Ross MP; Daniels TM; Nichols WL
    J Pediatr Hematol Oncol; 1997; 19(3):226-31. PubMed ID: 9201145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application.
    Kirkeby KM; Aronowitz P
    Am J Med; 2005 Jul; 118(7):805. PubMed ID: 15989925
    [No Abstract]   [Full Text] [Related]  

  • 10. Postoperative bleeding induced by topical bovine thrombin: report of two cases.
    Christie RJ; Carrington L; Alving B
    Surgery; 1997 Jun; 121(6):708-10. PubMed ID: 9186473
    [No Abstract]   [Full Text] [Related]  

  • 11. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
    Cmolik BL; Spero JA; Magovern GJ; Clark RE
    J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience.
    Sridharan M; Fylling KA; Ashrani AA; Chen D; Marshall AL; Hook CC; Cardel LK; Nichols WL; Pruthi RK
    Thromb Res; 2018 Nov; 171():14-21. PubMed ID: 30227314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature.
    Rodgers GM
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):86-8. PubMed ID: 21228719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin.
    Israels SJ; Leaker MT
    J Pediatr; 1997 Sep; 131(3):480-3. PubMed ID: 9329435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
    Savage WJ; Kickler TS; Takemoto CM
    Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
    Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
    Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of cephradine-induced acquired factor V inhibitors: a case report.
    Wu MT; Pei SN
    Ann Pharmacother; 2010 Oct; 44(10):1673-6. PubMed ID: 20807866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.
    Ofosu FA; Crean S; Reynolds MW
    Clin Ther; 2009 Apr; 31(4):679-91. PubMed ID: 19446142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical thrombins: benefits and risks.
    Lomax C; Traub O
    Pharmacotherapy; 2009 Jul; 29(7 Pt 2):8S-12S. PubMed ID: 19558279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient.
    Foster KN; Kim H; Potter K; Matthews MR; Pressman M; Caruso DM
    J Burn Care Res; 2010; 31(2):353-60. PubMed ID: 20182366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.